We are live on ! Find out more

Niagen Bioscience

NAGE

Market cap $184M

2.33 USD

-0.17

6.8%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

2.35

+0.02

0.86%

1 day

-6.8%

5 days

-4.12%

1 month

-20.21%

3 months

-29.82%

6 months

-50.74%

Year to date

-62.72%

1 year

-67.23%

5 years

-63.71%

10 years

-15.58%

About: Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.

Employees: 117

Consumer Staples Packaged Foods

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 5%

Neutral 90%

Negative 5%

Zacks Investment Research

Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to Decline

Niagen Bioscience (NAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to Decline

Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of the clinician-directed, prescription-only pharmaceutical-grade Niagen™ At-Home Injection Kit, featuring the Company's first ready-to-inject liquid formulation with Niagen™ (patented nicotinamide riboside, or NR), the most studied, high-quality NAD+ precursor brand available, now availabl.

Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion

Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Beauty--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the debut of Tru Niagen® Skincare, a permanent new category in the core Tru Niagen line, led by the Niagen® Skincare Innovation Lab. The inaugural product in this new category is Niagen NanoCloud™, the first dermatologist-tested topical product powered by Niagen® (patented nicotinamide riboside, or NR.

Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product

Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday, November 4, 2026, at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2026. The company will report the financial results in a press release after the close of regular stock market trading hours on Wednesda.

Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Award--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that Radicle Science and Council for Responsible Nutrition (CRN) honored Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, as the winner of the 2026 Annette Dickinson Trailblazer Award. “This award is incredibly special to me because I had the.

Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)

Niagen Bioscience to Present at LD Micro 20th Annual Main Event

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate in the 20th Annual LD Micro Main Event from Monday, October 19 to 21, 2026, in Los Angeles, CA. Niagen Bioscience Chief Executive Officer, Robert Fried, will present on Wednesday, October 21st at 1:30 p.m. PT. To register for the Niagen Bioscience webcast, pleas.

Niagen Bioscience to Present at LD Micro 20th Annual Main Event

Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of “Don't Get Old. Age Better.®,” a new brand campaign for its Niagen® (patented nicotinamide riboside, or NR) brand and sub-brands Tru Niagen® and Niagen Plus™, featuring 11-time world champion surfer Kelly Slater and more than 20 partners, across sports, entertainment, and medicine. The c.

Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.

Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a Start-Up Agreement with Mass General Brigham (MGB) to begin detailed planning for what is envisioned to be the largest and most comprehensive clinical trial of Niagen (patented nicotinamide riboside or NR) to date. “This agreement reflects the next stage of responsible NAD+ science,” said Rob Fried,.

Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial

Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the publication of independent preclinical research in Nature Communications led by a team at Sichuan Agricultural University identifying the CD38 enzyme as a primary driver of NAD+ decline in aging tissue, and that nicotinamide riboside (NR) restored NAD+ and improved placental, fetal, and offspring.

Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes

Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #BioPharma--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces today that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168, the Company's small molecule investigational drug candidate, targeting rare genetic diseases and aging-related disorders. The Compan.

Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth

See News Rankings

Price charts implemented using Lightweight Charts™